Introduction
Over the past 2 years, there has been increased interest in the biology of cilia and diseases associated with defects in cilia (ciliopathies) [1 ,2 ,3 ], including primary ciliary dyskinesia (PCD). PCD is a rare, inherited, usually autosomal recessive, disorder with impaired ciliary function leading to progressive sinopulmonary disease [4 ] . Approximately half of PCD patients have situs inversus totalis, reflecting dysmotility of embryonic nodal cilia. Male infertility is common, reflecting sperm tail dysmotility. Diagnosis of PCD has relied on identification of ciliary dysmotility and specific ciliary ultrastructural defects in outer dynein arms (ODAs), inner dynein arms (IDAs) or central apparatus. Because these tests are not readily available or standardized, the diagnosis is often delayed or missed or made incorrectly.
Clinical manifestations in primary ciliary dyskinesia
Upper and lower respiratory tract manifestations are cardinal features of PCD [5] [6] [7] [8] and often are present in the first month of life; however, the diagnosis is delayed because features overlap with other pediatric disorders [6] . Upper respiratory tract features include chronic year-round, nasal drainage that begins in the first weeks of life, chronic sinusitis that becomes apparent once the sinuses have developed and chronic otitis media that is most prevalent in the first years of life and often managed with tympanostomy tube placement [5] [6] [7] [8] . Lower respiratory features include neonatal respiratory distress, chronic productive cough, chronic bronchitis, recurrent pneumonia and bronchiectasis. Most patients have a history of neonatal respiratory distress with tachypnea, hypoxia and, occasionally, respiratory failure requiring mechanical ventilation that has been attributed to transient tachypnea of the newborn or neonatal pneumonia [7, 9, 10] . Chronic, yearround productive cough [5,7-9] often begins in the first weeks of life, but is attributed to recurrent viral infections, reflux and aspiration or cough-variant asthma. Chronic bronchitis and recurrent pneumonia with radiographic features of air trapping and atelectasis are common in childhood and lead to bronchiectasis that typically involves the middle and lower lobes and may occur in childhood [11 -13 ] and even in the first years of life [14 ] .
Laterality defects occur in approximately half of PCD patients [5, 7] . Indeed, the first reported cases in the early 1900s had situs inversus totalis (mirror image orientation of thoracoabdominal organs), chronic sinusitis and bronchiectasis, known as the Kartagener triad. A recent study [15 ] showed that heterotaxy (situs ambiguous or laterality defect other than situs inversus totalis) occurs with a prevalence of at least 6% and can be associated with complex congenital heart disease in PCD. In addition, a mouse model study [16 ] demonstrated that complex congenital heart disease was caused by mutations in one of the dynein genes (DNAH5), which accounts for over 20% of PCD cases (see PCD gene mutation analysis section below). These studies suggest that PCD-associated ciliary defects that affect embryonic nodal cilia can cause not only situs inversus totalis, but also heterotaxy and complex congenital heart disease [17 ]; therefore, infants with congenital heart disease and respiratory symptoms should be evaluated for PCD.
A variety of other features may be seen in PCD. Almost all men with PCD have infertility from impaired sperm motility. Hydrocephalus occurs rarely in PCD, although a frequent feature in mouse models of PCD, suggesting that ependymal ciliary dysmotility has greater implications in mice. Retinitis pigmentosa, polycystic kidney disease, liver cysts and biliary atresia (all features of ciliopathies of sensory cilia) have been reported rarely in PCD [5], suggesting that there may be overlap of diseases associated with defects in motile and sensory cilia.
Diagnostic tests
The specialized techniques required for PCD diagnostic tests are not standardized or readily available; therefore, referral to research centers or tertiary diagnostic centers may be needed [18 ] .
Ciliary ultrastructure
The cornerstone diagnostic test for PCD has been examination of ciliary ultrastructure by transmission electron microscopy. Each normal cilium contains an array of longitudinal microtubules, consisting of nine doublets arranged in an outer circle around a central pair (9 þ 2 pattern). Dynein arms are large protein complexes (including two to three heavy chains, two to four intermediate chains and at least eight light chains) that are attached to the nine microtubule doublets as distinct inner and outer 'arms' that are discernable on electron micrographs of ciliary cross-sections [1 ] (see Fig. 1 ). Dyneins generate the force for ciliary movement through microtubule sliding. The 9 þ 2 array of microtubules is maintained by intertubular linkages and accessory proteins (discernable on electron micrographs as radial spokes and nexin links) [1 ]. Several ciliary ultrastructural defects have been described, but the most frequent are absence or shortening of ODAs or IDAs, absence of radial spokes or loss of central pair of microtubules with transposition of a peripheral doublet to the center [5, 7] . A recent study [19 ] demonstrated a genetic diagnosis involving one of the dynein proteins (DNAH11), but normal ciliary ultrastructure and a subtle alteration in ciliary beat detectable by high-speed videomicroscopy, demonstrating that ultrastructural analysis alone will not identify all PCD cases. Absence of cilia, or acilia syndrome, has been described in a few families [20] .
Ciliary motility
In the past, light microscopic examination of ciliary beat was used as a screening test for PCD. Although this approach may identify immotile or markedly dyskinetic cilia, ciliary beat may appear normal in some cases of PCD. Digital high-speed videomicroscopy has been used to detect more subtle abnormalities in ciliary beat pattern and has demonstrated that certain ciliary beat patterns are associated with specific ultrastructural defects -immotile or limited flickering for ODA defects; low-amplitude stiff beat for isolated IDA defect or radial spoke defect; circular, whip-like beat for central microtubular defects such as transposition [21] . This specialized technique has been incorporated into the PCD evaluation at some PCD diagnostic centers [18 ] .
Nasal nitric oxide
Several studies [7, [22] [23] [24] have demonstrated that nasal nitric oxide is extremely low (10-15% of normal) in PCD patients, suggesting that nasal nitric oxide measurement may be a useful screening test for PCD. Because low nasal nitric oxide levels have been reported in a limited number of other disorders with overlapping clinical features, such as cystic fibrosis (CF) [7, 23, 25] , panbronchiolitis [26] and nasal polyposis [27] , confirmatory ciliary ultrastructure analysis or genetic mutation analysis or both are needed for a firm PCD diagnosis. At present, no Food and Drug Administration (FDA)-approved devices for measurement of nasal nitric oxide are available. Nasal nitric oxide measurement is used predominantly in research studies in the United States, but has become part of the diagnostic clinical testing at centers in Europe [19 ] . Nasal nitric oxide is measured by a noninvasive approach in which nasal air, aspirated through a catheter inserted at the opening of one nostril, is directed to a nitric oxide analyzer that typically uses ozonebased/NO 2 -based chemiluminescence for direct online measurement of nitric oxide [28] . The nasal catheter is inserted through a foam sleeve or olive that is wedged at the opening of the nostril to limit dilution of nasal nitric oxide by ambient air. During the measurement, the patient is asked to perform maneuvers to close the soft palate to limit contamination with gases exhaled from the lung, because exhaled nitric oxide from lower airways is typically much lower than nasal nitric oxide. These techniques have been used reproducibly in children over 5 years of age, but often are not possible in younger children who cannot cooperate with palate closure maneuvers. Measured nitric oxide concentration in parts per billion (ppb) varies with flow rate through the sampling line; however, nasal nitric oxide output (the product of transnasal flow rate and measured nitric oxide concentration) expressed in nl/min is constant over a wide range of transnasal flow rates and is the preferred nomenclature for reporting nasal nitric oxide measurements [28] . Cutoff values to delineate PCD from normal individuals range from 50 to 100 nl/min depending on the specific technique used [7, [22] [23] [24] . Recent studies [29 -33 ] have focused on optimizing and standardizing techniques for measuring nasal nitric oxide, especially in children under 5 years of age who are unable to cooperate with maneuvers to close the soft palate. The biologic role of nasal nitric oxide has not been defined; however, its postulated function is local host defence through its antimicrobial actions and regulation of ciliary motility [34, 35] .
Primary ciliary dyskinesia gene mutation analysis
Genetic diagnosis of PCD is challenging due to the extensive genetic heterogeneity and the large size of the disease-causing genes. To date, six genes have been linked with PCD ( Fig. 1) Genetic tests are very reliable because the presence of biallelic mutations in trans is diagnostic, and the mutation identification techniques are more highly standardized and easier to perform compared with ciliary ultrastructural analysis. Our knowledge about the PCD diseasecausing genes is still emerging in parallel with the technology development to handle mutation scanning for multiple large genes. For most recent information on PCD genetic tests, refer to http://www.genetests.org/, which is updated as new mutations are identified.
Other diagnostic tests
Mucociliary clearance measurement (a noninvasive assessment of ciliary function in the lower airways) is available at a limited number of PCD diagnostic centers and has been proposed as an adjunctive diagnostic test for PCD [46 ] .
Diagnostic approach
The criteria for the diagnosis of PCD include presence of characteristic phenotypic features and supporting laboratory studies. Only a few phenotypic features are apparent at birth (e.g., neonatal respiratory distress and laterality defects), but some phenotypic features become more obvious over the first years of life (e.g., chronic sinusitis and recurrent respiratory infections), and others may not be apparent until adulthood (e.g., male infertility). Therefore, the minimum number of phenotypic features varies with age from at least three in early childhood to typically five or more in late childhood and adulthood. The diagnostic approach to PCD (outlined in Table 1 ) is subject to modification with further development and refinement of diagnostic tests for PCD, as well as better definition of phenotypic features. The availability of genetic testing has enhanced our ability to make a definitive diagnosis of PCD, even in individuals with normal ciliary ultrastructure [19 ] . Further studies are needed to provide more extensive genetic testing as well as to standardize other diagnostic testing. In the meantime, careful distinction between a definitive diagnosis of PCD versus a probable or possible PCD diagnosis is important for clinical decision-making as well as for research studies. Criteria for a definitive diagnosis of PCD are presence of at least three (typically five or more) phenotypic features and either a genetic diagnosis (identification of two diseasecausing mutations) or identification of ciliary ultrastruc-tural defects that are specific for PCD (with no overlap with secondary ciliary defects that occur following airway infections or exposure to airway irritants). Individuals who have ultrastructural defects that may also be seen in secondary ciliary dyskinesia warrant repeat biopsy to determine whether the defect resolves as expected after recovery from an airway insult; however, persistence of the defect does not exclude a secondary dyskinesia from a chronic airway insult.
As reviewed above, nasal nitric oxide measurement is a useful screening test for PCD. In an individual with at least three phenotypic features of PCD and a very low nasal nitric oxide level, PCD is highly probable, particularly if diagnostic tests for CF are negative. Only highly specialized research centers have expertise with the other adjunctive tests (high-speed videomicroscopy and mucociliary clearance measurement) to define criteria that distinguish 'probable' versus 'possible' PCD. With further research and standardization, these tests may become more useful as diagnostic tests.
Conclusion
The diagnosis of PCD is evolving with better definition of phenotypic features and expansion of diagnostic tests. Nasal nitric oxide measurement is likely to become a useful screening test for PCD once it is standardized and available in the clinical setting. Identification of genes Ultrastructural ciliary defects that may overlap with secondary ciliary dyskinesia absence of central pair of microtubules (but no transposition) absence of cilia on multiple biopsies (ciliary aplasia) ciliary disorientation PCD genetic testing identifying only one disease-causing mutation Altered ciliary motility on high-speed videomicroscopy b Altered mucociliary clearance b PCD, primary ciliary dyskinesia. a Availability limited to research sites in the United States; more readily available outside United States. b Specialized diagnostic centers are developing criteria to define specific characteristics that may be consistent with 'probable PCD'. involved in PCD is a very active area of research. Currently, available genetic testing for PCD can identify approximately one-third of individuals with PCD. The other adjunctive tests for PCD require specialized equipment and expertise and are likely to be restricted to PCD research centers.
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